Bristol CEO Giovanni Caforio, AP

Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives

Bris­tol My­ers Squibb has seen set­back af­ter set­back for its chances to bring im­muno-on­col­o­gy block­buster Op­di­vo in­to new­ly di­ag­nosed brain can­cer pa­tients — a sort of holy grail for the field. De­spite hold­ing a slim hope Op­di­vo would turn around its chances, Bris­tol is ready to call it quits for now.

Bris­tol’s com­bo of Op­di­vo on top of stan­dard-of-care temo­zolo­mide plus ra­di­a­tion couldn’t beat place­bo in ex­tend­ing over­all sur­vival in pa­tients with new­ly di­ag­nosed MGMT-pos­i­tive glioblas­toma mul­ti­forme who pre­vi­ous­ly had their tu­mor sur­gi­cal­ly re­moved, the com­pa­ny said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.